Navigation Links
Mylan Announces Settlement Agreement for its First-to-File Generic Version of Vivelle-Dot®
Date:11/21/2011

PITTSBURGH, Nov. 21, 2011 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced that it has settled a patent litigation lawsuit with Novartis Pharmaceuticals Corporation related to Vivelle-Dot® (Estradiol Transdermal System USP, Twice-Weekly, 0.025 mg/day, 0.0375 mg/day, 0.05 mg/day and 0.075 mg/day and 0.1 mg/day).

Pursuant to the agreement, pending litigation will be dismissed, and Mylan will receive a patent license to begin selling generic versions of the product on Dec. 16, 2013, or earlier under certain circumstances. Additional details of the settlement are confidential, and the agreement itself is subject to review by the U.S. Department of Justice and the Federal Trade Commission.

Mylan was the first company to have filed a substantially complete abbreviated new drug application (ANDA) containing a Paragraph IV certification with the U.S. Food and Drug Administration (FDA) for Estradiol Transdermal System USP, Twice-Weekly. This product had total U.S. sales of $240 million for the 12 months ending Sept. 30, 2011, according to IMS Health.

Mylan Inc. ranks among the leading generic and specialty pharmaceutical companies in the world and provides products to customers in more than 150 countries and territories. The company maintains one of the industry's broadest and highest quality product portfolios supported by a robust product pipeline; operates one of the world's largest active pharmaceutical ingredient manufacturers; and runs a specialty business focused on respiratory, allergy and psychiatric therapies. For more information about Mylan, please visit www.mylan.com. For more information about generic drugs, please visit www.ChoosingGenerics.com.

This press release includes statements that constitute "forward-looking statements," including with regard to the settlement and the marketing of the product. These statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Because such statements inherently involve risks and uncertainties, actual future results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to: any legal or regulatory challenges to the settlement; strategies by competitors or other third parties to delay or prevent product introductions; risks inherent in legal and regulatory processes; and the other risks detailed in the company's periodic filings with the Securities and Exchange Commission. The company undertakes no obligation to update these statements for revisions or changes after the date of this release.


'/>"/>
SOURCE Mylan Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Mylan Successfully Upsizes and Completes Refinancing of Credit Facility
2. Mylan Applauds Obama Administrations Call to Create an "AIDS-Free Generation" Through Global Fight Against HIV/AIDS
3. Mylan to Acquire Pfizer Respiratory Delivery Platform
4. Mylan Receives Approval for Generic Version of MS Contin® Tablets
5. Mylan Launches First Generic Version of Exelon® Capsules in the U.K.
6. Mylans Dey Pharma Successfully Obtains Patent Reexamination Certificates for Two Perforomist® Patents
7. Matrix Laboratories Completes Name Change to Mylan Laboratories
8. Mylan Announces Femcon® Fe Settlement Agreement
9. Mylan Announces Intention to Refinance Existing Secured Credit Facility
10. Mylan Comments on Death of Company Co-Founder and Former Chairman and CEO Milan "Mike" Puskar
11. Mylan Applauds Study Highlighting $931 Billion in Savings for U.S. Health Care System Due to Generic Drugs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2016)... April 28, 2016  The blood testing market in ... according to Kalorama Information and The Freedonia Group in ... nucleic acid testing.  The healthcare research firm said that ... developing blood collection stations and in improving testing at ... Information,s report, Blood Testing Market in China ...
(Date:4/28/2016)... 28, 2016 Dr. Vivek Ahuja ... and Ste phen Schmidt ... leading provider of cloud-based software solutions for life sciences, today announced ... bring a wealth of insight to a growing business.  This will ... George Phillips joined ArisGlobal in the position of ...
(Date:4/28/2016)... April 28, 2016  ValGenesis, Inc., the ... Solutions (VLMS) today announced that a prominent ... sufferers of chronic kidney failure has selected ... their corporate validation process. The global medical ... solution to manage their validation processes electronically. ...
Breaking Medicine Technology:
(Date:4/29/2016)... Georgia (PRWEB) , ... April 29, 2016 , ... On ... rural hospitals across the Southeast, celebrated the signature of Gov. Nathan Deal on SB ... Rep. Geoff Duncan (R - Cumming), offers a 70% tax credit to individuals and ...
(Date:4/29/2016)... Fort Stewart, GA (PRWEB) , ... April 29, 2016 , ... ... on Monday, May 16, 2016, at its new location in the Exchange Furniture Mall ... including a raffle for a 50-inch Samsung Smart TV. Plus attendees will have the ...
(Date:4/29/2016)... ... April 29, 2016 , ... World Patent Marketing , ... exercise invention which aids in proper muscle development. , "The Gym & Exercise ... Director of World Patent Marketing. "Globalization has threatened the future growth of the ...
(Date:4/29/2016)... (PRWEB) , ... April 29, 2016 , ... Reltok Nasal ... and products for the head and neck/ear, nose and throat specialty, has added the ... The KOTLER NASAL AIRWAY™ is a newly patented safety device secured by ...
(Date:4/29/2016)... ... April 29, 2016 , ... CURE ... entirely on patients with cancer, today announced that Lynne Malestic, RN, of Eisenhower ... 2016 CURE® Extraordinary Healer® for Oncology Nursing , which honors nurses who have ...
Breaking Medicine News(10 mins):